User: Guest  Login
Title:

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

Document type:
Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Metzelder, SK; Schroeder, T; Finck, A; Scholl, S; Fey, M; Götze, K; Linn, YC; Kröger, M; Reiter, A; Salih, HR; Heinicke, T; Stuhlmann, R; Müller, L; Giagounidis, A; Meyer, RG; Brugger, W; Vöhringer, M; Dreger, P; Mori, M; Basara, N; Schäfer-Eckart, K; Schultheis, B; Baldus, C; Neubauer, A; Burchert, A
Abstract:
Preliminary evidence suggests that the multikinase inhibitor sorafenib has clinical activity in FLT3-ITD-positive (FLT3-ITD) acute myeloid leukemia (AML). However, the quality and sustainability of achievable remissions and clinical variables that influence the outcome of sorafenib monotherapy are largely undefined. To address these questions, we evaluated sorafenib monotherapy in 65 FLT3-ITD AML patients treated at 23 centers. All but two patients had relapsed or were chemotherapy-refractory af...     »
Journal title abbreviation:
Leukemia
Year:
2012
Journal volume:
26
Journal issue:
11
Pages contribution:
2353-9
Language:
eng
Fulltext / DOI:
doi:10.1038/leu.2012.105
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/22504140
Print-ISSN:
0887-6924
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX